Home The History of Synthetic Biology Designing Synthetic Biotics Pipeline Our People Leadership Board of Directors Founders and Advisors Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology Read more about Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU) Read more about Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU) Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference Read more about Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria Read more about Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates Read more about Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference Read more about Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018 Read more about Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018 Synlogic Joins Russell 3000® Index Read more about Synlogic Joins Russell 3000® Index Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria Read more about Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week® Read more about Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week® Pagination First page « First Previous page ‹ Previous … Page 14 Page 15 Page 16 Page 17 Current page 18 Page 19 Page 20 Page 21 Page 22 … Next page Next › Last page Last » Subscribe to Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology Read more about Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU) Read more about Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)
Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference Read more about Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria Read more about Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria
Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates Read more about Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates
Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference Read more about Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018 Read more about Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018
Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria Read more about Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week® Read more about Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®